Naked RNA Viruses

Industry

  • CPC
  • C12N2780/00
This industry / category may be too specific. Please go to a parent level for more data

Current Industry

Sub Industries

C12N2780/00011Naked RNA Viruses C12N2780/00021Viruses as such C12N2780/00022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2780/00023Virus like particles [VLP] C12N2780/00031Uses of virus other than therapeutic or vaccine C12N2780/00032Use of virus as therapeutic agent, other than vaccine C12N2780/00033Use of viral protein as therapeutic agent other than vaccine C12N2780/00034Use of virus or viral component as vaccine C12N2780/00041Use of virus, viral particle or viral elements as a vector C12N2780/00042virus or viral particle as vehicle C12N2780/00043viral genome or elements thereof as genetic vector C12N2780/00044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2780/00045Special targeting system for viral vectors C12N2780/00051Methods of production or purification of viral material C12N2780/00052relating to complementing cells and packaging systems for producing virus or viral particles C12N2780/00061Methods of inactivation or attenuation C12N2780/00062by genetic engineering C12N2780/00063by chemical treatment C12N2780/00064by serial passage C12N2780/00071Demonstrated in vivo effect C12N2780/00088For redistribution C12N2780/10011Narnaviridae C12N2780/10021Viruses as such C12N2780/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2780/10023Virus like particles [VLP] C12N2780/10031Uses of virus other than therapeutic or vaccine C12N2780/10032Use of virus as therapeutic agent, other than vaccine C12N2780/10033Use of viral protein as therapeutic agent other than vaccine C12N2780/10034Use of virus or viral component as vaccine C12N2780/10041Use of virus, viral particle or viral elements as a vector C12N2780/10042virus or viral particle as vehicle C12N2780/10043viral genome or elements thereof as genetic vector C12N2780/10044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2780/10045Special targeting system for viral vectors C12N2780/10051Methods of production or purification of viral material C12N2780/10052relating to complementing cells and packaging systems for producing virus or viral particles C12N2780/10061Methods of inactivation or attenuation C12N2780/10062by genetic engineering C12N2780/10063by chemical treatment C12N2780/10064by serial passage C12N2780/10071Demonstrated in vivo effect C12N2780/10088For redistribution

Patents Grantslast 30 patents

Patents Applicationslast 30 patents

  • Information Patent Application

    COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS TYPE 2 CO...

    • Publication number 20240139239
    • Publication date May 2, 2024
    • Asgard Therapeutics AB
    • Carlos Filipe Ribeiro Lemos Pereira
    • C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
  • Information Patent Application

    BACULOVIRUS EXPRESSION VECTOR

    • Publication number 20230390380
    • Publication date Dec 7, 2023
    • Intervet Inc.
    • Erwin VAN DEN BORN
    • C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
  • Information Patent Application

    METHODS AND COMPOSITIONS FOR THE EXPRESSION OF CONSTITUTIVELY ACTIV...

    • Publication number 20220347318
    • Publication date Nov 3, 2022
    • University of Utah Research Foundation
    • Mary Elizabeth Hartnett
    • A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
  • Information Patent Application

    CRISPRs

    • Publication number 20180201921
    • Publication date Jul 19, 2018
    • Excision BioTherapeutics, Inc.
    • Thomas Malcolm
    • C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...